NSE / BSEHealthcare
β‚Ή1099.60-8.40-0.76%
P/E18.8Mkt Capβ‚Ή90.64 K CrEV/EBITDA18.4

Zydus Lifesciences Limited

P/E18.8Mkt Capβ‚Ή90.64 K CrEV/EBITDA18.4
Company Profile

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 12.29% over 1Y
Monthly Returns

Historically, May has averaged the highest return (+6.1%); Oct the lowest (-2.1%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-3.2%Negative MonthJan 2026: -3.22%+4.2%Positive MonthFeb 2026: +4.21%-5.6%Negative MonthMar 2026: -5.56%+2.3%Positive MonthApr 2026: +2.35%+16.5%Positive MonthMay 2026: +16.52%+7.1%Positive MonthJun 2026: +7.05%-1.1%*Neutral MonthJul 2026: -1.13%β€”β€”β€”β€”β€”
2025-0.1%Neutral MonthJan 2025: -0.15%-9.7%Negative MonthFeb 2025: -9.67%+1.1%Neutral MonthMar 2025: +1.08%+0.2%Neutral MonthApr 2025: +0.23%+4.7%Positive MonthMay 2025: +4.75%+6.4%Positive MonthJun 2025: +6.43%-2.0%Neutral MonthJul 2025: -1.98%+1.1%Neutral MonthAug 2025: +1.12%+0.1%Neutral MonthSep 2025: +0.09%-0.7%Neutral MonthOct 2025: -0.73%-3.3%Negative MonthNov 2025: -3.31%-2.9%Negative MonthDec 2025: -2.93%
2024+10.4%Positive MonthJan 2024: +10.42%+23.9%Positive MonthFeb 2024: +23.88%+6.7%Positive MonthMar 2024: +6.65%-5.1%Negative MonthApr 2024: -5.14%+4.9%Positive MonthMay 2024: +4.94%+7.4%Positive MonthJun 2024: +7.36%+16.0%Positive MonthJul 2024: +16.04%-9.5%Negative MonthAug 2024: -9.49%-5.3%Negative MonthSep 2024: -5.31%-6.2%Negative MonthOct 2024: -6.22%-3.6%Negative MonthNov 2024: -3.56%+0.5%Neutral MonthDec 2024: +0.55%
2023+2.6%Positive MonthJan 2023: +2.60%+8.1%Positive MonthFeb 2023: +8.08%+5.6%Positive MonthMar 2023: +5.57%+5.8%Positive MonthApr 2023: +5.77%-3.4%Negative MonthMay 2023: -3.40%+16.1%Positive MonthJun 2023: +16.05%+9.8%Positive MonthJul 2023: +9.85%-2.3%Negative MonthAug 2023: -2.30%-1.6%Neutral MonthSep 2023: -1.65%-6.7%Negative MonthOct 2023: -6.72%+11.2%Positive MonthNov 2023: +11.16%+8.0%Positive MonthDec 2023: +8.03%
2022-15.9%Negative MonthJan 2022: -15.86%-11.4%Negative MonthFeb 2022: -11.41%-3.2%Negative MonthMar 2022: -3.22%+0.9%Neutral MonthApr 2022: +0.86%+7.6%Positive MonthMay 2022: +7.58%-5.7%Negative MonthJun 2022: -5.71%-2.9%Negative MonthJul 2022: -2.93%+9.2%Positive MonthAug 2022: +9.17%+2.3%Positive MonthSep 2022: +2.29%+12.2%Positive MonthOct 2022: +12.17%-5.6%Negative MonthNov 2022: -5.60%+2.5%Positive MonthDec 2022: +2.54%
2021β€”β€”β€”β€”β€”+4.3%Positive MonthJun 2021: +4.33%-9.2%Negative MonthJul 2021: -9.16%-5.5%Negative MonthAug 2021: -5.52%-0.3%Neutral MonthSep 2021: -0.30%-8.8%Negative MonthOct 2021: -8.83%-7.5%Negative MonthNov 2021: -7.53%+3.9%Positive MonthDec 2021: +3.88%
AvgΒ±SD-1.2%Β±8.6%+3.0%Β±12.9%+0.9%Β±4.8%+0.8%Β±3.5%+6.1%Β±6.4%+5.9%Β±6.4%+1.8%Β±8.5%-1.4%Β±6.3%-1.0%Β±2.5%-2.1%Β±7.6%-1.8%Β±6.6%+2.4%Β±3.6%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.202x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή15.12 K Crβ–² 39.7%
EBITDA Growthβ€”
Net Profitβ‚Ή5.78 K Crβ–² 67.8%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 96.2%
Revenue CAGR 5Y11.3%
EBITDA CAGR 5Y17.6%
Net Profit CAGR 5Y19.5%
NP Growth 1Y67.8%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή15.12 K Crβ€”β‚Ή5.78 K Crβ€”β€”27.3%39.7%67.8%
Mar 2024β‚Ή10.82 K Crβ€”β‚Ή3.44 K Crβ€”β€”21.9%23.9%125.1%
Mar 2023β‚Ή8.73 K Crβ€”β‚Ή1.53 K Crβ€”β€”11.2%11.4%78.2%
Mar 2022β‚Ή7.84 K Crβ€”β‚Ή858.00 Crβ€”β€”6.5%0.7%-41.9%
Mar 2021β‚Ή7.78 K Crβ€”β‚Ή1.48 K Crβ€”β€”11.6%22.6%4.5%
Mar 2020β‚Ή6.35 K Crβ€”β‚Ή1.41 K Crβ€”β€”12.5%5.1%-4.9%
Mar 2019β‚Ή6.04 K Crβ€”β‚Ή1.49 K Crβ€”β€”17.3%3.9%36.2%
Mar 2018β‚Ή5.81 K Crβ€”β‚Ή1.09 K Crβ€”β€”14.1%79.8%64.8%
Mar 2017β‚Ή3.23 K Crβ€”β‚Ή662.00 Crβ€”β€”10.0%-54.1%-67.5%
Mar 2016β‚Ή7.03 K Crβ€”β‚Ή2.04 K Crβ€”β€”32.5%33.1%60.3%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales4,0425,2847,0323,2315,8106,0376,3477,7807,8378,73210,81915,11613,795
Total Expenses3,2323,7504,4542,9094,1644,4004,9165,4685,9166,2776,7607,3807,636
EBIT / Operating Profit8101,5352,5783221,6461,6371,4322,3121,9212,4544,0597,7366,158
OPM %20%29%37%10%28%27%23%30%25%28%38%51%45%
Other Income305184174582208598848-102-1443451,076696962
Finance Costs42432611649023471135278391464504
Depreciation & Amortisation127212221251293358429451479489504524526
Profit Before Tax9461,4652,5046421,4971,7871,6171,6881,1642,0324,2407,4456,090
Tax %4%13%19%-3%27%17%13%13%26%25%19%22%-
Net Profit / PAT9041,2712,0386621,0911,4861,4131,4768581,5293,4425,7754,826
EPS (β‚Ή)8.8312.4219.906.4710.6614.5113.8014.428.3815.1134.2057.3947.95
Dividend Payout %20%19%16%50%33%24%25%24%30%40%9%19%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Zydus Lifesciences Limitedthis co.β‚Ή90.64 K Crβ‚Ή15.12 K Cr18.804.1918.3939.7%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Zydus Lifesciences Limited and the metrics that matter.

Browse the full Equiscale Academy